Nevirapine
  
Side effects 
	
		
Options: 
			
			Hide MedDRA Preferred Terms
			
		
	
	
| MedDRA Preferred Term | Side effect | Data for drug | Placebo | Labels | 
|  | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 
| Dermatitis | Rash | postmarketing — 4% - 24% | 1.5% - 14.9% | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Rash | Rash | postmarketing — 4% - 24% | 1.5% - 14.9% | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Liver function test abnormal | Liver function test abnormal | common, 1.2% - 6.7% | 0.9% - 1.5% |  |  |  |  |  |  |  |  |  |  |  | x | x | x | x | x | 
| Alanine aminotransferase increased | Alanine aminotransferase increased | common |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | x | x | 
| Headache | Headache | common, 0.7% - 4% | 0.4% - 1% | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Abdominal pain | Abdominal pain | common, 0.1% - 3% | 0% - 1% | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Gastrointestinal pain | Abdominal pain | common, 0.1% - 3% | 0% - 1% | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Diarrhoea | Diarrhoea | common, 0.2% - 4% | 0.5% - 1% | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Nausea | Nausea | common, 0.5% - 9% | 1% - 4% | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Hepatotoxicity | Hepatotoxicity | common, 2% - 2.4% |  |  |  |  |  | x | x | x | x | x | x |  |  | x | x | x | x | 
| Myalgia | Myalgia | postmarketing — 0.2% - 1.2% | 0% - 2% |  | x | x | x | x | x | x | x | x | x |  | x | x | x | x | x | 
| Musculoskeletal discomfort | Myalgia | postmarketing — 0.2% - 1.2% | 0% - 2% |  | x | x | x | x | x | x | x | x | x |  | x | x | x | x | x | 
| Arthralgia | postmarketing — 2% |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Drug eruption | Drug eruption | uncommon |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  | x | 
| Blood pressure increased | Blood pressure increased | uncommon |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | x | x | 
| Blood phosphorus decreased | Blood phosphorus decreased | uncommon |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | x | x | 
| Agranulocytosis | Agranulocytosis | postmarketing — 0.4% - 3.3% | 0% - 3% | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Asthenia | Fatigue | postmarketing — 0.2% - 5% | 0.3% - 4% | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Fatigue | Fatigue | postmarketing — 0.2% - 5% | 0.3% - 4% | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Toxic epidermal necrolysis | Toxic epidermal necrolysis | postmarketing, uncommon |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Erythema multiforme | Stevens-Johnson syndrome | postmarketing — 0.3% |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Erythema multiforme |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  | 
| Stevens-Johnson syndrome | Stevens-Johnson syndrome | postmarketing — 0.3% |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Anaphylactic shock | Anaphylactic shock | postmarketing — common |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Anaemia | Anaemia | postmarketing — 7% - 7.3% |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Angioedema | Angioedema | postmarketing — common |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Arthralgia | Arthralgia | postmarketing — 2% |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Blister | Blister | postmarketing |  | x | x | x | x | x | x | x | x | x | x | x | x |  | x |  |  | 
| Dermatitis bullous | Blister | postmarketing |  | x | x | x | x | x | x | x | x | x | x | x | x |  | x |  |  | 
| Bullous eruption | postmarketing |  | x | x | x | x | x | x | x | x | x | x | x | x |  | x |  |  | 
| Conjunctivitis | Conjunctivitis | postmarketing |  | x | x | x | x | x | x | x | x | x | x | x | x |  | x |  |  | 
| Oedema | Oedema | postmarketing |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  | 
| Eosinophilia | Eosinophilia | postmarketing, uncommon |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Body temperature increased | Body temperature increased | postmarketing — 1% - 2% |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Hepatitis | Hepatitis | postmarketing — 1.2% - 4% |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Hypersensitivity | Hypersensitivity | postmarketing, common |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Jaundice | Jaundice | postmarketing, uncommon |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Neutropenia | Neutropenia | postmarketing, 8.9% - 9% |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x |  |  | 
| Paraesthesia | Paraesthesia | postmarketing |  | x | x | x | x |  | x | x | x | x | x | x | x |  | x |  |  | 
| Paraesthesia skin | postmarketing |  |  |  |  |  | x |  |  |  |  |  |  |  |  |  |  |  | 
| Rhabdomyolysis | Rhabdomyolysis | postmarketing |  | x | x |  |  | x | x | x | x | x | x | x |  |  |  |  |  | 
| Mouth ulceration | Ulcerative stomatitis | postmarketing |  | x | x | x | x | x | x | x | x | x | x | x | x |  | x |  |  | 
| Urticaria | Urticaria | postmarketing, uncommon |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Vomiting | Vomiting | postmarketing, common |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Hepatic failure | Hepatic failure | postmarketing, rare |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Oral disorder | Oral lesion | postmarketing |  | x | x | x | x | x | x | x | x | x | x | x | x |  | x |  |  | 
| Hepatitis cholestatic | Hepatitis cholestatic | postmarketing |  | x | x | x | x | x | x | x | x | x | x | x | x |  | x |  |  | 
| Hepatic necrosis | Hepatic necrosis | postmarketing |  | x | x | x | x | x | x | x | x | x | x | x | x |  | x |  |  | 
| Malaise | Malaise | postmarketing |  | x | x | x | x | x | x | x | x | x | x | x | x |  | x |  |  | 
| Discomfort | Malaise | postmarketing |  | x | x | x | x | x | x | x | x | x | x | x | x |  | x |  |  | 
| Feeling abnormal | Malaise | postmarketing |  | x | x | x | x | x | x | x | x | x | x | x | x |  | x |  |  | 
| Ill-defined disorder | Malaise | postmarketing |  | x | x | x | x | x | x | x | x | x | x | x | x |  | x |  |  | 
| Pain | Ache | postmarketing |  | x | x | x | x | x | x | x | x | x | x | x | x |  | x |  |  | 
| Hepatitis fulminant | Hepatitis fulminant | rare |  |  |  |  |  |  |  |  |  |  |  |  | x | x | x | x | x | 
| Lymphadenopathy | Lymphadenopathy | postmarketing |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Face oedema | Face oedema | postmarketing |  | x | x | x | x | x | x | x | x | x | x | x | x |  |  |  |  | 
| Drug reaction with eosinophilia and systemic symptoms | Hypersensitive syndrome | postmarketing |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x |  |  | 
| Drug interaction | Drug interaction | postmarketing |  | x |  |  | x | x | x | x | x | x | x | x |  |  |  |  |  | 
| Somnolence | Somnolence | postmarketing |  | x | x | x | x | x | x | x | x | x | x | x | x |  | x |  |  | 
| Congenital anomaly | Congenital anomaly |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  | 
| Developmental delay | Congenital anomaly |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  | 
| Decreased appetite | Anorexia |  |  | x |  |  |  |  |  |  |  |  |  | x |  |  |  |  |  | 
| Autoimmune disorder | Autoimmune disorder |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | 
| Bone disorder | Bone disorder |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  | 
| Connective tissue disorder | Connective tissue disorder |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  | x | x | 
| Dermatitis exfoliative | Dermatitis exfoliative |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  | 
| Erythema nodosum | Erythema nodosum |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  |  | 
| Gastrointestinal disorder | Gastrointestinal disorder |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | x | x | 
| Basedow's disease | Basedow's disease |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | 
| Hepatitis toxic | Hepatitis toxic |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  |  | 
| Hypercholesterolaemia | Hypercholesterolaemia |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | 
| Hyperglycaemia | Hyperglycaemia |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | 
| Hypertriglyceridaemia | Hypertriglyceridaemia |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | 
| Blood triglycerides increased | Hypertriglyceridaemia |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | 
| Breast enlargement | Hypertrophy of breast |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | 
| Immune system disorder | Immune system disorder |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | x | x | 
| Inflammation | Inflammation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | 
| Insulin resistance | Insulin resistance |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | 
| Lipodystrophy acquired | Lipodystrophy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | 
| Liver disorder | Liver disorder |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  |  | 
| Hepatocellular injury | Liver disorder |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  |  | 
| Foetor hepaticus | Liver disorder |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  |  | 
| Necrosis | Necrosis |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  | 
| Nervous system disorder | Nervous system disorder |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | x | x | 
| Opportunistic infection | Opportunistic infection |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | 
| Pancreatitis | Pancreatitis |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  | x | x | 
| Neuropathy peripheral | Neuropathy peripheral |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  | x | x | 
| Pruritus | Pruritus |  |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Renal failure | Renal failure |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | 
| Thrombocytopenia | Thrombocytopenia |  |  |  | x | x | x | x | x | x | x | x | x |  | x |  |  | x | x | 
| Ulcer | Ulcer |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  | 
| Erythema | Erythema |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  | 
| Gamma-glutamyltransferase increased | Gamma-glutamyltransferase increased |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | x | x | 
| Aspartate aminotransferase increased | Aspartate aminotransferase increased |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | x | x | 
| Liver injury | Liver injury |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  | 
| Traumatic liver injury | Liver injury |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  | 
| Skin disorder | Unspecified disorder of skin and subcutaneous tissue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | x | x | 
| Rash erythematous | Rash erythematous |  |  | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | 
| Hepatic enzyme increased | Hepatic enzyme increased |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | x | x | 
| Skin exfoliation | Skin exfoliation |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  | 
| Vertical infection transmission | Vertical infection transmission |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  | 
| Hepatobiliary disease | Hepatobiliary disease |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | x | x | 
| Hepatitis acute | Hepatitis acute |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  |  | 
| Rash maculo-papular | Rash maculo-papular |  |  |  |  |  |  |  |  |  |  |  |  | x | x |  |  |  |  | 
| Transaminases increased | Transaminases increased |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | x | x | 
| Lipohypertrophy | Buffalo hump |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | 
| Chronic hepatitis B | Chronic hepatitis B |  |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  | 
| Surgery | Surgical intervention |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | 
| Hyperlactacidaemia | Hyperlactacidaemia |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | 
| Fat redistribution | Fat redistribution |  |  |  | x | x | x |  |  |  |  |  |  |  |  |  |  |  |  | 
| Rash papular | Rash papular |  |  |  |  |  |  |  |  |  |  |  |  | x |  |  |  |  |  | 
| Hypertransaminasaemia | Hypertransaminasaemia |  |  |  |  |  |  |  |  |  |  |  |  |  |  | x | x | x | x | 
	 
 
  Indications
	Information about indications was extracted from the indications and usage sections of the labels.
	
 
	  
	  
		| Side effects: | 41 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 42 | 
|---|
		| Source: | FDA | 
|---|
		 
	  
	  
		| Side effects: | 41 | 
|---|
		| Source: | FDA | 
|---|
		 
	  
	  
		| Side effects: | 42 | 
|---|
		| Source: | FDA | 
|---|
		 
	  
	  
		| Side effects: | 43 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 43 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 43 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 43 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 43 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 43 | 
|---|
		| Source: | FDA | 
|---|
		 
	  
	  
		| Side effects: | 47 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 54 | 
|---|
		| Source: | Health Canada | 
|---|
		 
	  
	  
		| Side effects: | 46 | 
|---|
		| Source: | Medsafe | 
|---|
		 
	  
	  
		| Side effects: | 58 | 
|---|
		| Source: | medicines.org.au | 
|---|
		 
	  
	  
		| Side effects: | 60 | 
|---|
		| Source: | EMA | 
|---|
		 
	  
	  
		| Side effects: | 61 | 
|---|
		| Source: | EMA | 
|---|
		 
	  
  
 
  
	Color scheme:
	  
	  standard – alternative
	  
	
	
|  |  | 100% | 
|  |  | 75% | 
|  |  | 50% | 
|  |  | 10% | 
|  |  | frequent (1% to 100%) | 
|  |  | infrequent (0.1% to 1%) | 
|  |  | rare (<0.1%) | 
|  |  | postmarketing | 
|  |  | 0% | 
|  |  | no frequency information | 
|  |  | not found on label |